Quick Order

BTN3A1 / CD277  Protein, Antibody, ELISA Kit, cDNA Clone

BTN3A1 / CD277 Related Area

BTN3A1 / CD277 Related Pathways

    BTN3A1 / CD277 Summary & Protein Information

    BTN3A1 / CD277 Background

    Subunit structure: Homodimer. {ECO:0000269|PubMed:22846996}.
    Subcellular location: Cell membrane {ECO:0000269|PubMed:21113407, ECO:0000269|PubMed:21918970, ECO:0000269|PubMed:22767497}; Single-pass type I membrane protein {ECO:0000269|PubMed:21113407, ECO:0000269|PubMed:21918970, ECO:0000269|PubMed:22767497}.
    Tissue specificity: Detected on T-cells, natural killer cells, dendritic cells and macrophages (at protein level). Ubiquitous. Highly expressed in heart, pancreas and lung, Moderately expressed in placenta, liver and muscle. {ECO:0000269|PubMed:20610803, ECO:0000269|PubMed:21113407, ECO:0000269|PubMed:21918970, ECO:0000269|PubMed:9149941}.
    Post-translational: N-glycosylated. {ECO:0000269|PubMed:20610803, ECO:0000269|PubMed:22846996}.
    Sequence similarity: Belongs to the immunoglobulin superfamily. BTN/MOG family. {ECO:0000305}.; Contains 1 B30.2/SPRY domain. {ECO:0000255|PROSITE-ProRule:PRU00548}.; Contains 2 Ig-like V-type (immunoglobulin-like) domains. {ECO:0000305}.
    General information above from UniProt

    BTN3A1 has the structure of a type I receptor of the Ig superfamily and is part of a family of seven BTN receptors encoded by genes in the MHC. BTN molecules are composed of two Ig domains (IgV, IgC2), a single transmembrane domain, and a large carboxyl-terminal domain termed B30.2 (or PRYSPRY) located in the cell cytoplasm. There are three human BTN3A loci, BTN3A1, BTN3A2, and BTN3A3, and clear orthologs of BTN3A molecules, now called CD277, are absent from the mouse genome. Despite its similarity to B7 molecules, BTN3A1 was proposed to act not as a coreceptor or costimulatory molecule, but rather to directly present pAg to the γδ TCR in a manner analogous to MHC-restricted peptide presentation. However, this model of BTN3A1 function has been challenged by conflicting data, which show pAg binding to a positively charged pocket in the cytosolic B30.2 domain, and that BTN3A1 does not directly engage the γδ TCR. This contradictory picture has emerged as a result of the complexity of the system and in particular by the use of endogenous and exogenous routes of Ag delivery in in vitro assays.

    Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    BTN3A1 / CD277 Alternative Name

    RP1-45P21.1,BT3.1, BTF5,BTN3.1,CD277, [Human]

    BTN3A1 / CD277 Related Studies

  • Rhodes DA, Chen H-C, Price AJ, et al. Activation of human γδ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin. Journal of immunology (Baltimore, Md : 1950). 2015;194(5):2390-2398.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"